AMGN Amgen Inc.

204.66
+1.77  (+1%)
Previous Close 202.89
Open 203.46
Price To Book 11.37
Market Cap 122,734,852,095
Shares 599,701,222
Volume 1,502,763
Short Ratio
Av. Daily Volume 2,979,803
Stock charts supplied by TradingView

NewsSee all news

  1. Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team

    THOUSAND OAKS, Calif., Oct. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan.

  2. Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

    THOUSAND OAKS, Calif. and PITTSBURGH, Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King

  3. Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The

  4. Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?

    THOUSAND OAKS, Calif., Sept. 26, 2019 /PRNewswire/ -- In recognition of World Heart Day on Sunday, September 29, Amgen (NASDAQ:AMGEN) today released findings from a global survey that evaluated worldwide heart attack

  5. Amgen To Webcast Investor Call At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2H 2020.
Tezepelumab - NAVIGATOR
Asthma
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Corlanor
Chronic Heart Failure
Approval announced May 17, 2018.
Erenumab
Migraine
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Approval announced December 1, 2017.
Repatha
Cardiovascular disease
sBLA approval announced January 5, 2017.
XGEVA
Multiple Myeloma
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
BLINCYTO
Ph+ R/R ALL
Phase 3 data released January 24, 2019 - primary endpoint met in rheumatoid arthritis trial. Non-Hodgkin’s lymphoma data also met primary endpoint showing clinical equivalence - August 22, 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
FDA approval announced June 13, 2019.
ABP 980 (Kanjinti; trastuzumab-anns)
Herceptin biosimilar
BsUFA date December 14, 2019.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Parsabiv
Secondary hyperparathyroidism (SHPT)
FDA Approval announced April 9, 2019.
EVENITY (Romosozumab)
Osteoporosis
Phase 3 interim analysis 1H 2020.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)
sNDA filing announced December 19, 2018. Estimated PDUFA date October 18, 2019.
Nplate (Romiplostim)
Immune thrombocytopenia (ITP)
Phase 3 data due 2019.
KYPROLIS (CANDOR)
Multiple Myeloma
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers
Phase 1 update at ESMO noted 54% PR rate for NSCLC patients (960mg); 1/12 for CRC patients.
AMG 510
Solid tumors
Phase 2/3 trial discontinued due to lack of efficacy.
CNP520
Alzheimer’s Disease
Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
BLINCYTO
Acute lymphoblastic leukemia (ALL) - pediatric

Latest News

  1. Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team

    THOUSAND OAKS, Calif., Oct. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan.

  2. Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

    THOUSAND OAKS, Calif. and PITTSBURGH, Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King

  3. Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The

  4. Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?

    THOUSAND OAKS, Calif., Sept. 26, 2019 /PRNewswire/ -- In recognition of World Heart Day on Sunday, September 29, Amgen (NASDAQ:AMGEN) today released findings from a global survey that evaluated worldwide heart attack

  5. Amgen To Webcast Investor Call At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on

  6. Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

    THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial

  7. Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical

  8. S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

    NEW YORK, Sept. 16, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the

  9. Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

    THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019, in

  10. Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

    THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD)

  11. Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019

    THOUSAND OAKS, Calif., Sept. 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma Workshop (IMW) 2019 in

  12. deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

    REYKJAVIK, Iceland, Sept. 11, 2019 /CNW/ -- deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to

  13. deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

    REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ -- deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare

  14. Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019

    THOUSAND OAKS, Calif., Sept. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG

  15. Amgen To Present At The Morgan Stanley Global Healthcare Conference

    THOUSAND OAKS, Calif., Sept. 5, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York City. Robert A. Bradway,

  16. Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer

    THOUSAND OAKS, Calif., Sept. 4, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference

  17. New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups

    THOUSAND OAKS, Calif., Aug. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 14 cardiovascular scientific research abstracts, including studies evaluating the safety and efficacy of

  18. Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

    THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ:CELG) in connection with its previously announced

  19. Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

    Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019 Bristol-Myers Squibb Company